Curative gene therapies for kidney diseases
Company is active
Event Year: 2022
Company is active
Event Year: 2022
Nephrogen is a biotechnology company focused on the development of curative gene therapies targeting kidney and pancreatic diseases. Kidney disease presents a significant healthcare challenge, affecting approximately one in seven Americans, which translates to around 50 million individuals. Currently, there is no cure for kidney disease, and its treatment consumes a substantial portion of the Medicare budget, accounting for nearly 10%. Nephrogen aims to address this unmet medical need through innovative gene therapy solutions.
Nephrogen is a biotechnology company focused on the development of curative gene therapies targeting kidney and pancreatic diseases. Kidney disease presents a significant healthcare challenge, affecting approximately one in seven Americans, which translates to around 50 million individuals. Currently, there is no cure for kidney disease, and its treatment consumes a substantial portion of the Medicare budget, accounting for nearly 10%. Nephrogen aims to address this unmet medical need through innovative gene therapy solutions.
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2020
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2020
Healthcare
Healthcare
Healthcare -> Therapeutics
Healthcare -> Therapeutics
Team size: 1
Hiring: No
Team size: 1
Hiring: No
